From the Wall Street Journal:

Eli Lilly & Co. said Wednesday it would plead guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act and pay $36 million to settle charges of off-label promotion of its Evista osteoporosis treatment in 1998.





Government regulators charged the company with promoting its Evista product for two other uses -- the prevention of breast cancer and for reducing cardiovascular risk -- neither of which have been approved by the Food and Drug Administration.